...
首页> 外文期刊>Journal of Clinical Microbiology >Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection.
【24h】

Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection.

机译:乙型肝炎核心抗原的免疫球蛋白M抗体:用于诊断乙型肝炎病毒感染的酶免疫法评估。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In acute and chronic hepatitis B, antibodies of the immunoglobulin M (IgM) class against the hepatitis B core antigen (anti-HBc IgM) have been demonstrated. For the determination of anti-HBc IgM, a sensitive enzyme immunoassay with anti-mu-coated flat-bottomed microtiter plates is described and evaluated. The specificity of the anti-HBc IgM test system was proven by pretreatment of presumed anti-HBc IgM-positive samples with anti-mu to block anti-HBc IgM. The test system was highly sensitive. In the acute stage of hepatitis B, anti-HBc IgM could be demonstrated in serum dilutions up to 10(-7) (mean titer, 10(-5)), and in sera from patients with chronic hepatitis B, the mean titer was 10(-3). In a study of unselected patients whose sera were sent at irregular intervals for testing, anti-HBc IgM persisted in a high percentage (52%) for at least 13 to 18 months after onset of illness despite the fact that these patients eliminated hepatitis B surface antigen (HBsAg) and produced antibodies to HBsAg (anti-HBs). By using the anti-HBc IgM test as an additional aid in the diagnosis of acute HBsAg-negative hepatitis, the hepatitis B etiology could be established in 13 of 42 patients (31.4%). Investigations of the prevalence of anti-HBc IgM in different groups of patients with chronic hepatitis B infection showed 89.4% anti-HBc IgM-positive results in patients with chronic active hepatitis B, 60% in patients with HBsAg-negative chronic active hepatitis, 58.2% in patients with primary liver carcinoma and markers of hepatitis B infections, and 34.9% in healthy carriers of HBsAg.
机译:在急性和慢性乙型肝炎中,已经证明了针对乙型肝炎核心抗原(抗-HBc IgM)的免疫球蛋白M(IgM)类抗体。为了确定抗HBc IgM,描述并评估了具有抗mu包被的平底微量滴定板的灵敏酶免疫法。抗HBc IgM检测系统的特异性通过用抗Mu阻断抗HBc IgM预处理假定的抗HBc IgM阳性样品而得到证明。测试系统非常敏感。在乙型肝炎的急性期,抗HBc IgM的血清稀释度最高可达10(-7)(平均滴度为10(-5)),在慢性乙型肝炎患者的血清中,平均滴度为10(-3)。在一项未经选择的以不定期间隔进行血清检查的患者的研究中,抗HBc IgM发病后至少13到18个月仍以高百分比(52%)持续存在,尽管这些患者消除了乙肝表面抗原(HBsAg)和产生的HBsAg抗体(抗HBs)。通过使用抗-HBc IgM试验作为辅助诊断急性HBsAg阴性肝炎,可以在42例患者中的13例(31.4%)中确定乙型肝炎的病因。对不同组慢性乙型肝炎患者中抗HBc IgM患病率的调查显示,慢性活动性乙型肝炎患者中抗HBc IgM阳性率为89.4%,HBsAg阴性慢性活动性肝炎患者中为60%,58.2原发性肝癌和乙型肝炎感染标志物患者中的比例为30%,健康HBsAg携带者的比例为34.9%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号